DK309387D0 - Humant erythropoietin-gen samt expression deraf i transficerede celler - Google Patents

Humant erythropoietin-gen samt expression deraf i transficerede celler

Info

Publication number
DK309387D0
DK309387D0 DK309387A DK309387A DK309387D0 DK 309387 D0 DK309387 D0 DK 309387D0 DK 309387 A DK309387 A DK 309387A DK 309387 A DK309387 A DK 309387A DK 309387 D0 DK309387 D0 DK 309387D0
Authority
DK
Denmark
Prior art keywords
humant
expression
transfected cells
erythropoietin
genes
Prior art date
Application number
DK309387A
Other languages
English (en)
Other versions
DK309387A (da
DK173067B1 (da
Inventor
Jerry S Powell
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25374134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK309387(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Washington filed Critical Univ Washington
Publication of DK309387D0 publication Critical patent/DK309387D0/da
Publication of DK309387A publication Critical patent/DK309387A/da
Application granted granted Critical
Publication of DK173067B1 publication Critical patent/DK173067B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2795/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
DK198703093A 1986-06-27 1987-06-17 Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa DK173067B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87942386A 1986-06-27 1986-06-27
US87942386 1986-06-27

Publications (3)

Publication Number Publication Date
DK309387D0 true DK309387D0 (da) 1987-06-17
DK309387A DK309387A (da) 1987-12-28
DK173067B1 DK173067B1 (da) 1999-12-13

Family

ID=25374134

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198703093A DK173067B1 (da) 1986-06-27 1987-06-17 Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa

Country Status (17)

Country Link
US (3) US5688679A (da)
EP (1) EP0255231B1 (da)
JP (1) JPS63126488A (da)
KR (1) KR970009935B1 (da)
CN (2) CN1044133C (da)
AT (1) ATE76431T1 (da)
AU (1) AU611088B2 (da)
BR (1) BR8703269A (da)
CA (1) CA1341361C (da)
DE (1) DE3779206D1 (da)
DK (1) DK173067B1 (da)
ES (1) ES2037083T3 (da)
FI (1) FI95393C (da)
GR (1) GR3004707T3 (da)
NO (1) NO303398B1 (da)
PT (1) PT85193B (da)
WO (1) WO1988000241A1 (da)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US4974929A (en) * 1987-09-22 1990-12-04 Baxter International, Inc. Fiber optical probe connector for physiologic measurement devices
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
CA2183551A1 (en) * 1993-11-10 1995-05-18 Babru B. Samal Gene therapy vector for the treatment of low or defective red blood cell production
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US6699672B1 (en) * 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US6897066B1 (en) * 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
WO1999029732A2 (en) 1997-12-08 1999-06-17 Lexigen Pharmaceuticals Corporation Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
BR9905868A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
EP1157118A4 (en) * 1999-03-01 2002-07-17 Insight Strategy & Marketing POLYNUCLEOTID ENCODING A POLYPEPTIDE WITH HEPARANASE ACTIVITY AND ITS EXPRESSION IN GENETICALLY MODIFIED CELLS
PL203797B1 (pl) * 1999-04-09 2009-11-30 Ortho Mcneil Pharm Inc Kompozycje farmaceutyczne erytropoetyny
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
EP1200479B1 (en) 1999-08-09 2006-02-01 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
PL358582A1 (en) 2000-06-29 2004-08-09 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
ATE428790T1 (de) 2000-09-25 2009-05-15 Genetronics Inc Verbessertes system zur regulation der transgenexpression
DE60219961T8 (de) 2001-02-02 2008-04-17 Ortho-Mcneil Pharmaceutical, Inc. Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
WO2003045423A1 (en) * 2001-11-28 2003-06-05 Ortho-Mcneil Pharmaceutical, Inc. Erythropoietin dosing regimen for treating anemia
AU2002357784B2 (en) 2001-12-04 2008-07-31 Merck Patent Gmbh Immunocytokines with modulated selectivity
US7129267B2 (en) * 2002-03-11 2006-10-31 Janssen Pharmaceutica N.V. Methods for SHP1 mediated neuroprotection
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
ATE466085T1 (de) * 2002-09-09 2010-05-15 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
KR101086660B1 (ko) 2002-12-17 2011-11-24 메르크 파텐트 게엠베하 Ｇｄ2 에 결합하는 마우스 14.18 항체의 인간화 항체(ｈ14.18) 및 그것의 ｉｌ-2 와의 융합
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20060269552A1 (en) * 2003-06-09 2006-11-30 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
ES2387028T3 (es) 2003-12-31 2012-09-12 Merck Patent Gmbh Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
US7423139B2 (en) * 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
US20050238628A1 (en) * 2004-04-08 2005-10-27 Blau Carl A Methods for treating cancer
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
US20090143255A1 (en) * 2007-11-30 2009-06-04 Funkhouser Gary P Methods and Compositions for Improving Well Bore Stability in Subterranean Formations
CN101939443B (zh) 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
US20120172299A1 (en) 2008-09-23 2012-07-05 F. Hoffmann-La Roche Ag Purification of erythropoietin
PT2342223T (pt) * 2008-09-26 2017-07-07 Lilly Co Eli Polipéptidos de eritropoetina animal modificados e suas utilizações
CA2745329C (en) 2008-12-04 2022-07-12 Opko Curna, Llc Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
WO2013120500A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
US10066001B2 (en) 2013-03-15 2018-09-04 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
JP6245299B2 (ja) * 2016-04-27 2017-12-13 バクスアルタ ゲーエムベーハー 組換え安定細胞クローン、その産生およびその使用
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IT1185503B (it) * 1984-01-11 1987-11-12 Univ New York Cloni di odna di eritropietina umana
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
EP0217822B1 (en) * 1985-02-13 1993-05-12 Scios Nova Inc. Human metallothionein-ii promoter in mammalian expression system
US4751084A (en) * 1986-02-26 1988-06-14 Monsanto Company Tissue plasminogen activator from normal human colon cells
DE3789678T2 (de) * 1986-02-27 1994-08-11 Snow Brand Milk Products Co Ltd Herstellung von erythropoietinproduzierenden Zellen und Verfahren zur Herstellung von Erythropoietin mit Verwendung dieser Zellen.
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition

Also Published As

Publication number Publication date
ES2037083T3 (es) 1993-06-16
EP0255231B1 (en) 1992-05-20
DK309387A (da) 1987-12-28
US20020045255A1 (en) 2002-04-18
CN1044133C (zh) 1999-07-14
CN101041819A (zh) 2007-09-26
PT85193B (pt) 1990-08-31
KR970009935B1 (ko) 1997-06-19
AU611088B2 (en) 1991-06-06
NO880863L (no) 1988-04-26
US6682910B2 (en) 2004-01-27
KR880007726A (ko) 1988-08-29
FI880899A (fi) 1988-02-26
BR8703269A (pt) 1988-03-15
NO880863D0 (no) 1988-02-26
WO1988000241A1 (en) 1988-01-14
US5688679A (en) 1997-11-18
FI880899A0 (fi) 1988-02-26
EP0255231A1 (en) 1988-02-03
CN87104424A (zh) 1988-04-27
JPS63126488A (ja) 1988-05-30
ATE76431T1 (de) 1992-06-15
NO303398B1 (no) 1998-07-06
FI95393C (fi) 1996-01-25
US20020137145A1 (en) 2002-09-26
AU7475787A (en) 1988-01-07
DE3779206D1 (de) 1992-06-25
FI95393B (fi) 1995-10-13
DK173067B1 (da) 1999-12-13
US6867020B2 (en) 2005-03-15
GR3004707T3 (da) 1993-04-28
CA1341361C (en) 2002-05-21
PT85193A (en) 1987-07-01

Similar Documents

Publication Publication Date Title
DK309387A (da) Humant erythropoietin-gen samt expression deraf i transficerede celler
DE3750755D1 (de) Anti-sense-Regulierung von Genexpression in Pflanzenzellen.
ATE87317T1 (de) Fsh.
DE69128893D1 (de) Genetische veränderung von endothelzellen
DE68915070D1 (de) Zellkultur-Reaktor.
DE3381438D1 (de) Herstellung und expression struktureller gene.
ATE391175T1 (de) Multidrug resistenz gen
DE3688900T2 (de) Expression von Protein C.
FI962268A (fi) Homologinen, rekombinanttinen vasta-aineilmentämisjärjestelmä rottien tai hiirien soluille
AU3668389A (en) Exogenous gene expression vector containing chick beta-actin gene promoter
ATE75778T1 (de) Immunosuppressionsfaktor.
DE68927104T2 (de) Gentherapie unter verwendung von genschmelzen für genetische und erworbene störungen
DE3673436D1 (de) Gene fuer biologisch aktive proteine.
IT8721615A0 (it) Clonaggio del gene dell'isoamilasi.
FR2564857B1 (fr) Vecteurs d'expression du facteur ix et lignees cellulaires produisant le facteur ix actif.
ATE55618T1 (de) Gene fuer biologisch aktive proteine.
ATE51873T1 (de) Herstellung und expression struktureller gene.

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired